---
document_datetime: 2025-12-03 13:51:46
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/enhertu-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: enhertu-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.6948724
conversion_datetime: 2025-12-19 13:44:00.636323
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Enhertu

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                      | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA /  | A.5 Change in the name and/or address of a | 27/11/2025                          | N/A                                         |                                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000310421                     | manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted                                                                                                                                                                                                                                                                                                 |            |            |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000281778 | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.e The change relates to a biological active substance or a starting material/reagent/intermediate used in the manufacture of a biological/immunological product - Accepted | 13/11/2025 | N/A        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Renewal - 1 year / EMA/R/0000282648   | - Renewal -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 18/09/2025 | 21/11/2025 | SmPC, Annex II and PL | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Enhertu, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. Sections 4.8, 5.1 and 5.2 of the SmPC as well as section 4 of the |

<div style=\"page-break-after: always\"></div>

|                                       |                                                                                                                                                  |            |     | Package Leaflet have been updated to reflect the final results from study DS-8201-A-U306 (DESTINY- Gastric04) in order to fulfil SOB 006.1. This is a phase 3, multicentre, 2 - arm, randomised, open- label study of Enhertu in subjects with HER2 - positive metastatic and/or unresectable gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a trastuzumab-containing regimen. Annex II.E was also amended to delete SOB 006.1 which is considered fulfilled as part of this annual renewal as well as to update the due date for specific obligation SOB 007 pertaining to study D967SC00001 (DESTINY-Lung04 study) from Q4 2025 to Q4 2026 due to slower than expected accrual of PFS by BICR events. Version 10.0 of the RMP has also been submitted. In addition the MAH took the opportunity to include the missing reference to E433 for polysorbate 80 in section 6 of the Package Leaflet, to update the contact details of the Icelandic local representative in the Package Leaflet and to correct some translations mistakes in the BG, CZ, DA, DE, EL, ES, ET, FI, FR, HR, IS, IT, LT, LV, MT, NL, NO, PL, PT, SK, SL and SV annexes.   |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000291445 | This was an application for a group of variations. B.I ACTIVE SUBSTANCE - B.I.z Other variation - Accepted B.II. FINISHED PRODUCT - B.II.z Other | 27/08/2025 | N/A |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|                                       | variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |     |                   |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------|
| Variation type IA /                   | A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted  | 26/06/2025 | N/A | EMA/VR/0000279297 |
| Variation type II /                   | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.e The change relates to a biological active substance or a starting material/reagent/intermediate used in the manufacture of a biological/immunological product - Accepted | 12/06/2025 | N/A | EMA/VR/0000263542 |
| Variation type II / EMA/VR/0000247231 | B.II.g) Design Space and post approval change management protocol - B.II.g.2                                                                                                                                                                                                                                                                                                                                                                                                                                               | 05/06/2025 | N/A |                   |

<div style=\"page-break-after: always\"></div>

|                            | Introduction of a post approval change management protocol related to the finished product - Accepted   |            |     |             |
|----------------------------|---------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| PSUR / EMA/PSUR/0000257882 | - -                                                                                                     | 10/07/2025 | N/A | Maintenance |